← Back to Search

Anti-infective

Trimethoprim Sulfamethoxazole for Chronic Obstructive Pulmonary Disease

Phase 1 & 2
Waitlist Available
Led By Matthew Sims, MD, PhD
Research Sponsored by William Beaumont Hospitals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Currently treated with steroids
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 months
Awards & highlights

Study Summary

This trial will test whether treating airway colonization with the fungus Pneumocystis jirovecii (PJ) will improve outcomes for patients with acute exacerbations of COPD.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease Exacerbation Acute

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are currently taking steroids as part of your treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the COPD Assessment Test
Secondary outcome measures
Clearance of PJ From Treated Patients
Durability of Clearance of PJ From Treated Patients
Interval Between Exacerbations of COPD
+10 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TMP-SMXExperimental Treatment1 Intervention
Suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
Group II: PlaceboPlacebo Group1 Intervention
Suspension with placebo by mouth every 12 hours for 10 days

Find a Location

Who is running the clinical trial?

William Beaumont HospitalsLead Sponsor
149 Previous Clinical Trials
113,035 Total Patients Enrolled
Matthew Sims, MD, PhDPrincipal InvestigatorWilliam Beaumont Hospitals
1 Previous Clinical Trials
20,614 Total Patients Enrolled

Media Library

Trimethoprim Sulfamethoxazole (Anti-infective) Clinical Trial Eligibility Overview. Trial Name: NCT05418777 — Phase 1 & 2
Chronic Obstructive Pulmonary Disease Research Study Groups: TMP-SMX, Placebo
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: Trimethoprim Sulfamethoxazole Highlights & Side Effects. Trial Name: NCT05418777 — Phase 1 & 2
Trimethoprim Sulfamethoxazole (Anti-infective) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05418777 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research currently calling for new participants?

"According to clinicaltrials.gov, the trial is actively searching for potential patients and has been since it was initially posted on September 28th 2022; no new updates have transpired since then."

Answered by AI

Does my profile meet the criteria to partake in this trial?

"This clinical trial seeks 30 individuals aged 40 to 89 years that have been diagnosed with COPD and admitted due to an exacerbation. To be eligible, they must also produce a sputum sample, not have severely impaired kidney function (CrCl ≥ 60), AST/ALT values ≤ 5 times the upper limit of normal, previously enrolled in EPIC Study with Pneumocystis jirovecii detected in their sputum sample and currently being treated with steroids. Furthermore, participants need to demonstrate willingness and ability to provide consent for this study."

Answered by AI

What aims is this experiment attempting to accomplish?

"This three-month long study aims to gauge the Change in COPD Assessment Test. Secondary objectives consist of Interval between exacerbations of COPD, measured by days; Need for medications to treat COPD, quantified through the amount of drugs used; and Need for mechanical ventilation, evaluated based on participant's necessity thereof."

Answered by AI

Is this study open to individuals who have not yet reached the age of 85?

"Participants that are accepted into this trial must have attained the age of 40, but should not be older than 89."

Answered by AI

What is the sample size for this medical research endeavor?

"Affirmative. According to the info logged on clinicaltrials.gov, this investigative trial is open for recruitment and was initially announced on September 28th 2022. The project requires 30 individuals from a single site."

Answered by AI
~0 spots leftby Mar 2025